GeneFerm Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
GeneFerm Biotechnology has a total shareholder equity of NT$892.8M and total debt of NT$45.3M, which brings its debt-to-equity ratio to 5.1%. Its total assets and total liabilities are NT$1.2B and NT$282.5M respectively. GeneFerm Biotechnology's EBIT is NT$153.6M making its interest coverage ratio 47.2. It has cash and short-term investments of NT$120.2M.
Key information
5.1%
Debt to equity ratio
NT$45.25m
Debt
| Interest coverage ratio | 47.2x |
| Cash | NT$120.15m |
| Equity | NT$892.84m |
| Total liabilities | NT$282.54m |
| Total assets | NT$1.18b |
Financial Position Analysis
Short Term Liabilities: 1796's short term assets (NT$397.1M) exceed its short term liabilities (NT$189.9M).
Long Term Liabilities: 1796's short term assets (NT$397.1M) exceed its long term liabilities (NT$92.7M).
Debt to Equity History and Analysis
Debt Level: 1796 has more cash than its total debt.
Reducing Debt: 1796's debt to equity ratio has reduced from 15.6% to 5.1% over the past 5 years.
Debt Coverage: 1796's debt is well covered by operating cash flow (420.6%).
Interest Coverage: 1796's interest payments on its debt are well covered by EBIT (47.2x coverage).